As previously mentioned in our June 2021 article, “Are Benzene Contaminated Sunscreens Safe to Use?“, and August 2021 article, "Johnson & Johnson Recalls Neutrogena and Aveeno Sunscreen Over Benzene Contamination Concerns", popular sunscreen manufacturer, Johnson & Johnson has issued a … More
Main Navigation Menu
➤ About the Law Offices of Thomas J. Lamb
PRACTICE AREAS
➤ Asbestos and Mesothelioma Claims
➤ Benzene Diseases and Cancers Claims
➤ Pharmaceutical Drug Injury Lawsuits
➤ Breast Implants Lymphoma Cancer Cases
➤ Philips Breathing Devices Recall Lawsuits
➤ GenX Water Contamination Cancer Cases
➤ Free Case Evaluation by Lawyer Tom Lamb
INFORMATION
➤ Frequently Asked Questions (FAQs)
➤ Medical Records Copying Cost Laws
➤ Client Resources: Legal, Medical, and More
➤ Collection of Articles by Our Law Firm
Please know that you can use our Quick Contact Form to tell us a bit about your case.
Recent Articles
Philips Ventilators Recall: What The Company Knew and When, What It Did or Did Not Do, and More FDA Findings Released November 2021
This is an important update about the June 2021 Philips ventilators recall using some remarkable findings set forth in an FDA Form 483 issued to Philips Respironics on November 9, 2021. First, from a November 16, 2021 article, "FDA inspection turns up more problems for Philips Respironics", … More
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
Background: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the efficacy and safety of nivolumab [(Opdivo)], an anti-PD-1 antibody, in these … More
Immunotherapy combination maintains OS advantage in malignant pleural mesothelioma
The combination of [ Opdivo and Yervoy ] maintained its survival advantage over chemotherapy with at least 3 years of follow-up among patients with unresectable malignant pleural mesothelioma, according to CheckMate 743 study results. Researchers observed the benefit of the first-line … More
GenX Contamination May Be More Toxic Than EPA Initially Thought
Since July 2021, when we posted our last GenX article, “EPA Petitioned to Reconsider Requiring Chemours to Fund PFAS Testing“, it has been determined that GenX contamination in the Cape Fear region may pose more threats than initially thought. These findings come following the Environmental … More
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
Background: There is a preclinical rationale for inhibiting angiogenesis in mesothelioma. We aimed to assess the efficacy and safety of the anti-VEGFR-2 antibody ramucirumab combined with gemcitabine in patients with pretreated malignant pleural mesothelioma [ as a second-line treatment … More